Trial Profile
A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2020
Price :
$35
*
At a glance
- Drugs Cipargamin (Primary) ; Artemether/lumefantrine; Piperaquine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis
- 16 Nov 2020 Results published in the Antimicrobial Agents and Chemotherapy
- 02 Sep 2016 Status changed from completed to discontinued.
- 19 Jul 2016 Status changed from discontinued to completed.